latest news releases from the newsroom
TransAct Technologies, Inc.
TransAct Technologies Epic 950(r) Printer Selected by Indiana Casinos
HAMDEN, Conn., Oct. 2, 2008 (GLOBE NEWSWIRE) -- TransAct Technologies Incorporated (Nasdaq:TACT), a global leader in market-specific printers for transaction-based industries, today announced that the Horseshoe Hammond, Hoosier Park and Indiana Live! casinos located in Indiana have selected the Epic 950(r) ticket printer for their respective slot games. Combined, these properties have over 7,000 slot games.
Old Dominion Freight Line, Inc.
Old Dominion Freight Line's Third Quarter Conference Call On the Internet
THOMASVILLE, N.C., Oct. 2, 2008 (GLOBE NEWSWIRE) -- Old Dominion Freight Line, Inc. (Nasdaq:ODFL) announced today that it plans to release its 2008 third quarter financial results before opening of trading on Thursday, October 23, 2008. The Company will also hold a conference call to discuss its financial results and outlook at 10:00 a.m. (Eastern Time) on Thursday, October 23, 2008.
Carver Bancorp, Inc.
Carver Bancorp, Inc. Names Paul Hagan Interim CFO
NEW YORK, Oct. 2, 2008 (GLOBE NEWSWIRE) -- Carver Bancorp, Inc. (Nasdaq:CARV), the holding company for Carver Federal Savings Bank, today announced that Paul Hagan, a former CFO of Reliance Bancorp and accountant at KPMG LLP, has joined Carver as interim Chief Financial Officer. Mr. Hagan replaces Roy Swan, who left Carver earlier this month after joining a leading investment bank.
The Descartes Systems Group Inc.
Lufthansa Extends Membership to Descartes GF-X Global Electronic Cargo Booking Exchange
WATERLOO, Ontario, Oct. 2, 2008 (GLOBE NEWSWIRE) -- Descartes Systems Group, a global on-demand software-as-a-service (SaaS) logistics solutions provider, announced that Lufthansa Cargo has signed a three-year extension of its membership to the Descartes GF-X Exchange to support Lufthansa Cargo's global electronic cargo bookings.
DARA BioSciences, Inc.
DARA BioSciences Announces Completion of Toxicology Studies for Its PPAR-delta/gamma Agonist, DB959
RALEIGH, N.C., Oct. 2, 2008 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage pharmaceutical company, announced the completion of all toxicology studies necessary for entering Phase 1 clinical trials for its PPAR-delta/gamma agonist, DB959. DB959 is a novel insulin sensitizer designed to correct the insulin resistance of Type 2 diabetes. In pre-clinical studies, the drug has demonstrated potent PPAR-delta activity, which the Company believes will be beneficial in treating cholesterol and lipoprotein abnormalities in diabetics. DB959 has also demonstrated two additional benefits in pre-clinical studies: (i) a significant reduction in weight gain of approximately 70% compared to Avandia(r), and (ii) synergistic effects on insulin sensitivity arising from both PPAR delta and PPAR gamma activity.